Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA2 | Q15349 | 8/20 | 0.38 |
| ▸ | RPS6KA3 | P51812 | 3/20 | 0.38 |
| ▸ | RPS6KA1 | Q15418 | 2/20 | 0.38 |
| ▸ | RPS6KA6 | Q9UK32 | 2/20 | 0.38 |
| ▸ | SCD5 | Q86SK9 | 3/20 | 0.36 |
| ▸ | SCD | O00767 | 2/20 | 0.36 |
| ▸ | ITK | Q08881 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | BUB1 | O43683 | 4/20 | 0.34 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15520582 | 0.89 | ALK (0.33) | SCD5SCDITKALDH1A1 | |
| SCHEMBL13770435 | 0.89 | CHEK1 (0.34) | — | |
| SCHEMBL947608 | 0.89 | RPS6KA2 (0.41) | RPS6KA2RPS6KA3RPS6KA1RPS6KA6SCD5 | |
| SCHEMBL948893 | 0.86 | KLKB1 (0.40) | RPS6KA2RPS6KA3RPS6KA1RPS6KA6ALDH1A1 | |
| SCHEMBL950481 | 0.86 | ALDH1A1 (0.42) | RPS6KA2RPS6KA3RPS6KA1RPS6KA6SCD5 | |
| SCHEMBL31060778 | 0.86 | ALDH1A1 (0.41) | RPS6KA2RPS6KA3RPS6KA1RPS6KA6SCD5 | |
| SCHEMBL950079 | 0.86 | ALDH1A1 (0.41) | RPS6KA2RPS6KA3RPS6KA1RPS6KA6SCD5 | |
| SCHEMBL949615 | 0.86 | RPS6KA2 (0.40) | RPS6KA2RPS6KA3RPS6KA1RPS6KA6SCD5 | |
| SCHEMBL949097 | 0.85 | RPS6KA2 (0.40) | RPS6KA2RPS6KA3RPS6KA1RPS6KA6SCD5 | |
| SCHEMBL949246 | 0.83 | SMN1; SMN2 (0.38) | RPS6KA2RPS6KA3RPS6KA1RPS6KA6KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2294065-A1 | INDOLYL- PYRIDONE DERIVATIVES HAVING CHECKPOINT KINASE 1 INHIBITORY ACTIVITY | Vernalis (R&D) Ltd. (GB) | 2011-03-16 | — | — | EP | claimed |
| US-20110021498-A1 | INDOLYL- PYRIDONE DERIVATIVES HAVING CHECKPOINT KINASE 1 INHIBITORY ACTIVITY | VERNALIS (R & D) LTD (GB) | 2011-01-27 | — | — | US | claimed |
| US-20200361905-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | VERNALIS R&D LTD (GB) | 2020-11-19 | — | — | US | disclosed |
| US-10696652-B2 | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity | VERNALIS (R&D) LTD. (GB) | 2020-06-30 | — | — | US | disclosed |
| US-20170298043-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | VERNALIS (R&D) LTD. (GB) | 2017-10-19 | — | — | US | disclosed |
| US-9604975-B2 | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity | VERNALIS (R&D) LTD (GB) | 2017-03-28 | — | — | US | disclosed |
| US-20150099736-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | VERNALIS (R&D) LTD (GB) | 2015-04-09 | — | — | US | disclosed |
| US-8916591-B2 | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity | VERNALIS (R&D) LTD (GB) | 2014-12-23 | — | — | US | disclosed |
| EP-2294065-B1 | INDOLYL-PYRIDONE DERIVATIVES HAVING CHECKPOINT KINASE 1 INHIBITORY ACTIVITY | VERNALIS R&D LTD (GB) | 2014-03-19 | — | — | EP | disclosed |
| US-20110021498-A1 | INDOLYL- PYRIDONE DERIVATIVES HAVING CHECKPOINT KINASE 1 INHIBITORY ACTIVITY | VERNALIS (R & D) LTD (GB) | 2011-01-27 | — | — | US | disclosed |
| US-20110021498-A1 | INDOLYL- PYRIDONE DERIVATIVES HAVING CHECKPOINT KINASE 1 INHIBITORY ACTIVITY | VERNALIS (R & D) LTD (GB) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298043-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | CHEK1, CHEK2, RAD1 | RPS6KA2 889/4885RPS6KA3 564/4885RPS6KA1 460/4885 |
| US-20200361905-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | CHEK2, CHEK1, BUB1B | RPS6KA2 530/4885RPS6KA3 528/4885RPS6KA1 371/4885 |
| US-20150099736-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | CHEK1, CHEK2, RAD1 | RPS6KA2 889/4885RPS6KA3 564/4885RPS6KA1 460/4885 |
| US-10696652-B2 | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity | CHEK2, CHEK1, BUB1B | RPS6KA2 530/4885RPS6KA3 528/4885RPS6KA1 371/4885 |
| US-20110021498-A1 | INDOLYL- PYRIDONE DERIVATIVES HAVING CHECKPOINT KINASE 1 INHIBITORY ACTIVITY | CHEK1, CHEK2, BUB1 | RPS6KA2 666/4885RPS6KA3 523/4885RPS6KA1 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.